Back to BIIB Stock Lookup

BIIB Related Corporate News

May 30, 2013 06:56 AM Biogen (BIIB) Sees Delay to Launch of TECFIDERA in EU Until H213

May 13, 2013 07:31 AM Biogen (BIIB) BLA for ELOCTATE Accepted by FDA

Mar 27, 2013 04:25 PM Biogen Idec (BIIB) Affirms Receipt of FDA Approval for TECFIDERA as MS Treatment

Mar 27, 2013 03:35 PM UPDATE: Biogen Idec (BIIB) wins FDA approval for MS pill

Mar 22, 2013 08:28 AM Biogen Idec (BIIB) TECFIDERA Receives Positive EMA CHMP Opinion

Mar 20, 2013 07:45 AM Biogen Idec (BIIB) PLEGRIDY Met Primary Endpoint in Phase 3 ADVANCE

Mar 18, 2013 07:32 AM Biogen Idec (BIIB), Elan (ELN) to Present Positive Data for Tysabri on MS Supporting JCV

Mar 12, 2013 07:31 AM Biogen Idec (BIIB) Submits BLA to FDA for rFVIIIFc as Hemophilia A Treatment

Mar 11, 2013 06:29 AM Elan Corp. (ELN) Sees Tysabri Closing Within Weeks; Approves $1B Buyback

Mar 4, 2013 07:32 AM Biogen Idec (BIIB) BLA for rFIXFc Accepted by FDA

Feb 6, 2013 06:25 AM Elan (ELN) Restructures Tysabri Collaboration w/ Biogen (BIIB); Will Get $3.25B Upfront

Jan 4, 2013 07:30 AM Biogen Idec (BIIB) Submits BLA to FDA for rFIXFc Marketing Approval

Jan 3, 2013 07:31 AM Biogen Idec (BIIB) Says EMPOWER Missed Primary Endpoint

Dec 10, 2012 10:17 AM Isis Pharma (ISIS) Higher Following New Antisense Development Collaboration (BIIB)

Nov 29, 2012 03:10 PM Biogen Idec (BIIB) Opens New Facility in Research Triangle Park

Oct 12, 2012 08:14 AM Biogen (BIIB) Reports Significant Data from BG-12 Phase 3 in Treating MS

Sep 26, 2012 07:33 AM Biogen Idec (BIIB), Swedish Orphan Report Encouraging Data for B-Long; Plan to Submit BLA

Sep 19, 2012 05:05 PM Biogen Idec (BIIB) Reports Publication of Significant Results from Phase 3 DEFINE and CONFIRM

Sep 10, 2012 08:39 AM Biogen Idec (BIIB) Sells Royality, Other Rights for BENLYSTA to DRI Capital

Aug 13, 2012 06:28 AM Elan Corp (ELN) Approves Spin-Off of Neotope Biosciences Unit

Aug 1, 2012 03:16 PM Isis Pharma (ISIS) Reports Encouraging Data for Antisense Compounds on DM1

Jun 29, 2012 08:04 AM Biogen Idec (BIIB), Isis Pharma (ISIS) Enter Exclusive DM1 Treatment Development Collaboration

Jun 27, 2012 07:03 AM Sunesis Pharma (SNSS) Gets $1.5M Milestone from Biogen (BIIB) Under Multi-Kinase Inhibitor Agreement

Apr 26, 2012 01:48 PM Biogen (BIIB), Elan (ELN) Update on Long-Term Safety, Efficacy Profile of TYSABRI in MS Patients

Apr 24, 2012 07:34 AM Biogen Idec (BIIB) Says CONFIRM Phase 3 for BG-12 Met Endpoints in Second Trial

Mar 27, 2012 04:53 PM Hansen Medical (HNSN) Appoints Former Biogen COO Rohn to Board

Mar 14, 2012 10:24 AM Biogen Idec (BIIB), MAKScientific Enter MS Drug Development, Commercialization Agreement

Feb 28, 2012 07:34 AM Biogen (BIIB) Announces Approval of AVONEX PEN, Dose Titration Regimen from FDA

Jan 31, 2012 10:14 AM TYSABRI Lifts Biogen (BIIB) to Q4 Beat; FY12 Outlook is Muted

Jan 23, 2012 06:37 AM Biogen (BIIB), Elan (ELN) Get FDA Approval for TYSABRI Label Change; Will Epand MS Market

Jan 20, 2012 04:05 PM FRA Grants Quest Diagnostics (DGX) First Market Authorized Antibody-based Blood Test to Help Stratify PML Risk in MS Patients

Jan 9, 2012 09:08 AM Biogen Idec (BIIB) Updates on Four Growth Strategies for FY12

Jan 4, 2012 08:34 AM Biogen (BIIB), Isis Pharma (ISIS) Enter ISIS-SMNRx Development Collaboration; Isis May Get Up to $299M

Dec 6, 2011 06:54 AM Samsung and Biogen Idec (BIIB) Enter Joint Venture to Develop, Manufacture and Market Biosimilars

Oct 27, 2011 08:50 AM Biogen (BIIB), Portola Pharma Enter $553.5M Oral Syk Inhibitor Collaboration

Oct 26, 2011 07:52 AM Biogen Idec (BIIB) Reports BG-12 Met Primary Endpoint in Two Phase 2s

Oct 24, 2011 06:29 AM Biogen (BIIB), Abbott (ABT) Report DAC HYP Met Primary Endpoint in SELECT Trial

Oct 19, 2011 06:45 AM Biogen Idec (BIIB), Elan (ELN) Report Encouraging TYSABRI Data

Sep 6, 2011 08:16 AM Biogen (BIIB) to Acquire 100% of Dompé, Expand Presence in Europe

Jul 26, 2011 06:45 AM Biogen (BIIB), Swedish Orphan Reports Encouraging Data from rFVIIIFc Phase 1/2a

Jul 25, 2011 09:14 AM Biogen Idec (BIIB) Receives Conditional Approval for FAMPYRA from the EC

Jul 5, 2011 07:10 AM Biogen Idec (BIIB) Updates on Novel MS Treatment

Jun 22, 2011 07:20 AM Biogen (BIIB), Elan (ELN) Notes EC Approves Anti-JCV Status in SmPC for TYSABRI

Jun 6, 2011 07:32 AM Biogen (BIIB) Reports Strong Data from AVONEX in Reducing Flu-Like Symptoms

May 20, 2011 08:21 AM Committee for Medicinal Products for Human Use of the European Medicine Agency Recommends FAMPYRA to Adult Patients with Multiple Sclerosis

May 16, 2011 07:09 AM Biogen Idec (BIIB) Receives TGA Approval for FAMPYRA

Apr 21, 2011 08:18 AM Biogen (BIIB) Rallying 20% in Pre-Market as Results from BG-12 MS Pill Trial Very Strong

Apr 19, 2011 06:55 AM Biogen (BIIB) Receives Positive Opinion from CHMP for AVONEX PEN

Apr 18, 2011 07:38 AM CHMP Okays Addition of Additional Risk Factor to Label of Biogen (BIIB) and Elan's (ELN) TYSABRI

Mar 31, 2011 08:44 AM Biogen Idec (BIIB) Enrolls First Patient in Phase III Trial for ALS Treatment

Back to BIIB Stock Lookup